GlaxoSmithKline CEO Emma Walmsley has reportedly received a pay cut of 14 per cent after the company missed an internal profit target for sales of routine vaccinations against other diseases.
According the pharmaceutical giant’s annual report, Ms Walmsley’s total remuneration for 2020 came in at seven million pounds (€8.2 million).
The cut, according to comments by Non-Executive Director Urs Rohner in the report, partly reflected a missed internal profit target for biopharmaceuticals, mainly due to lockdowns stopping people from receiving routine vaccinations which cut into the CEO’s bonus.
Ms Walmsley was appointed CEO in 2017, and has made great strides in the company’s restructuring efforts, as it works to split its consumer and pharmaceutical businesses.
GlaxoSmithKline has been among the frontrunners in the effort to develop COVID-19 vaccines and treatments, with the company’s offering, which was developed in conjunction with the University of Oxford, having been approved for use in over 50 countries.
Last month, pharmaceutical chiefs came under fire as EU leaders prioritised the acceleration of COVID-19 vaccination rollouts, with pharmaceutical companies being pressed to abide by delivery commitments.
Denise Xuereb on Verdala Hotel: ‘Meaningful design begins with respect for place and heritage’
Verdala Wellness Hotel opened its doors in August 2025 and has since received three European Property Awards.
‘Few generations have the privilege of taking a company into its second century’ – Michael Farrugia
His comments were made at The Cause for Applause employee recognition programme.
Ionut Alexia named Group Financial Controller at Tauss Holdings
Tauss Holdings is associated with the Travers Tauss family and encompasses a portfolio of companies operating across different areas of ...
Döhle Corporate and Trust Services Limited appoints Graziella Vella as Executive Director
Graziella Vella has been with the company for the past four years.
